

LEGENDS TO THE FIGURES

Fig 1. Protein sequence of wild-type staphylokinase, SakSTAR. Numbering starts with the NH₂-terminal amino acid of mature full length staphylokinase.

Fig 2. Time course of neutralizing activities (left panel) and specific IgG against administered agent (right panel) following intra-arterial infusion of SakSTAR (open circles, n= 9), SakSTAR(K74A) (closed circles, n= 11) or SakSTAR(K74A,E75A, R77A) (open squares, n= 6) in patients with peripheral arterial occlusion. The data represent median values and interquartile ranges, in µg/mL.

Fig 3. Protein sequence of wild-type staphylokinase, SakSTAR with indicated amino acid substitutions.

squares: single amino acid substitutions; circles: combined (2 to 3) amino acid to Ala substitutions.

Fig 4. Temperature stability of SakSTAR, (A); SakSTAR(K74Q,E80A,D82A,K130T, K135R), (B); SakSTAR(E65D,K74R,E80A,D82A,K130T,K135R), (C); and SakSTAR(K35A,E65D,K74Q,E80A,D82A, K130T,K135R), (D).



(O): 4°C; (●): 20°C; (▽): 37°C; (▼): 56°C; (□): 70°C.

Fig 5. Time course of neutralizing activities (left panel) and specific IgG against administered agent (right panel) following intra-arterial infusion of SakSTAR (circles, n=), SakSTAR(K74Q,E80A,D82A,K130T,K135R) (squares, n= 6) or SakSTAR(E65D,K74R,E80A,D82A,K130T,K135R) (triangles, n= 6) in patients with peripheral arterial occlusion. The data represent median values and 15-85 percentile ranges, in µg/mL.

New Staphylokinase Derivatives
Desiré José Collen
Atty. Docket No. 702-001525

1														14
Ser	Ser	Ser	Phe	Asp	Lys	Gly	Lys	Tyr	Lys	Lys	Gly	Asp	Asp	
15														28
Ala	Ser	Tyr	Phe	Glu	Pro	Thr	Gly	Pro	Tyr	Leu	Met	Val	Asn	
29														42
Val	Thr	Gly	Val	Asp	Ser	Lys	Gly	Asn	Glu	Leu	Leu	Ser	Pro	
43														56
His	Tyr	Val	Glu	Phe	Pro	Ile	Lys	Pro	Gly	Thr	Thr	Leu	Thr	
57														70
Lys	Glu	Lys	Ile	Glu	Tyr	Tyr	Val	Glu	Trp	Ala	Leu	Asp	Ala	
71														84
Thr	Ala	Tyr	Lys	Glu	Phe	Arg	Val	Val	Glu	Leu	Asp	Pro	Ser	
85														98
Ala	Lys	Ile	Glu	Val	Thr	Tyr	Tyr	Asp	Lys	Asn	Lys	Lys	Lys	
99														112
Glu	Glu	Thr	Lys	Ser	Phe	Pro	Ile	Thr	Glu	Lys	Gly	Phe	Val	
113														126
Val	Pro	Asp	Leu	Ser	Glu	His	Ile	Lys	Asn	Pro	Gly	Phe	Asn	
127														136
Leu	Ile	Thr	Lys	Val	Val	Ile	Glu	Lys	Lys					

Figure 1




[illegible]

Figure 3





Figure 5



000001 0/982/60